madman
Super Moderator
Aquablation, a treatment for benign prostatic hyperplasia, has demonstrated positive outcomes with low morbidity in large prostates (>80 mL). A study found significant and sustained improvements in patient symptoms, including a decrease in International Prostate Symptom Score and an increase in maximum urinary flow rate. Aquablation showed reproducible clinical outcomes and a low re-treatment rate at 5 years. While the study lacked a comparison group, previous trials showed similar results. Aquablation offers a viable option for men seeking to preserve continence, erectile function, and ejaculatory function.
Key Points:
Key Points:
- The study reports 5-year safety and efficacy outcomes of the Aquablation procedure for treating symptomatic benign prostatic hyperplasia with large-volume prostate glands
- 101 men with moderate to severe symptoms and prostate volumes between 80 and 150 mL underwent robotic-assisted Aquablation in a multicenter trial
- The study successfully met its safety and efficacy goals at 3 months based on outcomes of transurethral resection typically performed in smaller prostates
- Patient symptoms significantly improved with a decrease in International Prostate Symptom Score and an increase in maximum urinary flow rate
- Regression analysis showed a 50% reduction in PSA levels
- Aquablation demonstrated durable efficacy and low retreatment rates in men with large prostates (80-150 mL) at 5 years of follow-up
